Which has better earnings and valuation, OBI or ABC?

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.65M 2,464.23 -C$424.66K -C$6.00 N/A Abcam £350.40M 0.00 N/A £0.06 N/A

Is OBI or ABC more profitable?

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Ondine Biomedical -1,117.06% -1,411.54% -159.71% Abcam N/A N/A N/A

Do analysts recommend OBI or ONT?

Oxford Nanopore Technologies has a consensus target price of GBX 198.60, suggesting a potential upside of 24.13%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Nanopore Technologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83

Does the media favor OBI or ONT?

In the previous week, Oxford Nanopore Technologies had 5 more articles in the media than Ondine Biomedical. MarketBeat recorded 7 mentions for Oxford Nanopore Technologies and 2 mentions for Ondine Biomedical. Oxford Nanopore Technologies' average media sentiment score of 0.80 beat Ondine Biomedical's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ondine Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Nanopore Technologies 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer OXB or OBI?

Oxford Biomedica currently has a consensus price target of GBX 580.85, indicating a potential upside of 30.31%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oxford Biomedica is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to OXB or OBI?

In the previous week, Ondine Biomedical had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Ondine Biomedical and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.75 beat Ondine Biomedical's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ondine Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend OBI or AVCT?

Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 41.43%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings & valuation, OBI or AVCT?

Ondine Biomedical has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.65M 2,464.23 -C$424.66K -C$6.00 N/A Avacta Group £113K 2,902.51 -£30.08M -£9.66 N/A

Ondine Biomedical (OBI) Competitors

C$12.00 +0.11 (+0.90%)

As of 11:40 AM Eastern

Compare

OBI vs. ABC, ONT, OXB, SLN, and AVCT

Should you buy Ondine Biomedical stock or one of its competitors? Ondine Biomedical's main competitors and comparable companies include Abcam (ABC), Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), Silence Therapeutics (SLN), and Avacta Group (AVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ondine Biomedical compare to Abcam?

Ondine Biomedical (LON:OBI) and Abcam (LON:ABC) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Abcam	N/A	N/A	N/A

31.3% of Ondine Biomedical shares are held by institutional investors. 29.0% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,464.23	-C$424.66K	-C$6.00	N/A
Abcam	£350.40M	0.00	N/A	£0.06	N/A

In the previous week, Ondine Biomedical had 2 more articles in the media than Abcam. MarketBeat recorded 2 mentions for Ondine Biomedical and 0 mentions for Abcam. Ondine Biomedical's average media sentiment score of 0.00 equaled Abcam'saverage media sentiment score.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Abcam	Neutral

Summary

Abcam beats Ondine Biomedical on 6 of the 9 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Ondine Biomedical (LON:OBI) and Oxford Nanopore Technologies (LON:ONT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Ondine Biomedical has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,464.23	-C$424.66K	-C$6.00	N/A
Oxford Nanopore Technologies	£235M	6.64	-£175.21M	-£15.10	N/A

Oxford Nanopore Technologies has a net margin of -54.66% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Nanopore Technologies' return on equity of -35.45% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%

Oxford Nanopore Technologies has a consensus target price of GBX 198.60, suggesting a potential upside of 24.13%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

31.3% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 18.3% of Oxford Nanopore Technologies shares are owned by institutional investors. 29.0% of Ondine Biomedical shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ondine Biomedical has a beta of 0.308, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.912, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Oxford Nanopore Technologies had 5 more articles in the media than Ondine Biomedical. MarketBeat recorded 7 mentions for Oxford Nanopore Technologies and 2 mentions for Ondine Biomedical. Oxford Nanopore Technologies' average media sentiment score of 0.80 beat Ondine Biomedical's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ondine Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oxford Nanopore Technologies beats Ondine Biomedical on 10 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Ondine Biomedical (LON:OBI) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

In the previous week, Ondine Biomedical had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Ondine Biomedical and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.75 beat Ondine Biomedical's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ondine Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ondine Biomedical has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.20	-£143.51M	-£26.92	N/A
Ondine Biomedical	C$2.65M	2,464.23	-C$424.66K	-C$6.00	N/A

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 31.3% of Ondine Biomedical shares are held by institutional investors. 25.8% of Oxford Biomedica shares are held by insiders. Comparatively, 29.0% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oxford Biomedica currently has a consensus price target of GBX 580.85, indicating a potential upside of 30.31%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oxford Biomedica is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Oxford Biomedica has a net margin of -17.85% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Biomedica's return on equity of -48.56% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

Oxford Biomedica has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.308, meaning that its stock price is 69% less volatile than the broader market.

Summary

Oxford Biomedica beats Ondine Biomedical on 10 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Ondine Biomedical (LON:OBI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

In the previous week, Ondine Biomedical had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Ondine Biomedical and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Ondine Biomedical	Neutral

31.3% of Ondine Biomedical shares are owned by institutional investors. 29.0% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Silence Therapeutics has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Silence Therapeutics' return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

Silence Therapeutics has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Ondine Biomedical	C$2.65M	2,464.23	-C$424.66K	-C$6.00	N/A

Summary

Ondine Biomedical beats Silence Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Ondine Biomedical compare to Avacta Group?

Ondine Biomedical (LON:OBI) and Avacta Group (LON:AVCT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Ondine Biomedical has a beta of 0.308, meaning that its share price is 69% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Avacta Group has a consensus target price of GBX 99, indicating a potential upside of 41.43%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ondine Biomedical has a net margin of -1,117.06% compared to Avacta Group's net margin of -33,961.06%. Ondine Biomedical's return on equity of -1,411.54% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Ondine Biomedical has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,464.23	-C$424.66K	-C$6.00	N/A
Avacta Group	£113K	2,902.51	-£30.08M	-£9.66	N/A

In the previous week, Ondine Biomedical had 2 more articles in the media than Avacta Group. MarketBeat recorded 2 mentions for Ondine Biomedical and 0 mentions for Avacta Group. Ondine Biomedical's average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Avacta Group	Neutral

31.3% of Ondine Biomedical shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 29.0% of Ondine Biomedical shares are held by company insiders. Comparatively, 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ondine Biomedical beats Avacta Group on 8 of the 15 factors compared between the two stocks.

Get Ondine Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBI vs. The Competition

Export

Metric	Ondine Biomedical	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	C$6.52B	C$3.95B	C$7.16B	C$2.90B
Dividend Yield	N/A	3.61%	2.54%	6.17%
P/E Ratio	-2.09	11.92	272.69	367.26
Price / Sales	2,464.23	1,324.45	618.51	83,754.59
Price / Cash	1.99	44.06	28.78	27.89
Price / Book	1,453.45	16.85	11.04	6.93
Net Income	-C$424.66K	-C$22.72M	C$3.47B	C$5.89B
7 Day Performance	6.81%	-2.67%	-1.50%	-0.13%
1 Month Performance	-6.52%	11.15%	7.35%	2.83%
1 Year Performance	-16.33%	54.04%	23.84%	21.66%

Ondine Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBI Ondine Biomedical	N/A	C$12.00 +0.9%	N/A	-19.5%	C$6.23B	C$2.65M	N/A	N/A	News Coverage High Trading Volume
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
ONT Oxford Nanopore Technologies	2.9276 of 5 stars	GBX 170 +3.3%	GBX 193.25 +13.7%	-2.7%	£1.66B	£235M	N/A	1,281
OXB Oxford Biomedica	2.5899 of 5 stars	GBX 522.70 +3.1%	GBX 580.85 +11.1%	-7.4%	£613.73M	£168.74M	N/A	891	High Trading Volume
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OBI) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, ONT, OXB, SLN, and AVCT

How does Ondine Biomedical compare to Abcam?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Summary

How does Ondine Biomedical compare to Silence Therapeutics?

Summary

How does Ondine Biomedical compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, ONT, OXB, SLN, and AVCT

How does Ondine Biomedical compare to Abcam?

Is OBI or ABC more profitable?

Do institutionals and insiders hold more shares of OBI or ABC?

Which has better earnings and valuation, OBI or ABC?

Does the media prefer OBI or ABC?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Which has higher valuation and earnings, OBI or ONT?

Is OBI or ONT more profitable?

Do analysts recommend OBI or ONT?

Do institutionals & insiders have more ownership in OBI or ONT?

Which has more volatility and risk, OBI or ONT?

Does the media favor OBI or ONT?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Does the media refer more to OXB or OBI?

Which has higher earnings & valuation, OXB or OBI?

Do institutionals and insiders believe in OXB or OBI?

Do analysts prefer OXB or OBI?

Is OXB or OBI more profitable?

Which has more risk & volatility, OXB or OBI?

Summary

How does Ondine Biomedical compare to Silence Therapeutics?

Does the media favor SLN or OBI?

Do insiders & institutionals have more ownership in SLN or OBI?

Is SLN or OBI more profitable?

Which has better valuation and earnings, SLN or OBI?

Summary

How does Ondine Biomedical compare to Avacta Group?

Which has more volatility and risk, OBI or AVCT?

Do analysts recommend OBI or AVCT?

Is OBI or AVCT more profitable?

Which has better earnings & valuation, OBI or AVCT?

Does the media favor OBI or AVCT?

Do insiders and institutionals have more ownership in OBI or AVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools